Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

CYP3A Phenotyping × Docetaxel × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 411 Carcinoma, Non-Small-Cell Lung 372 Prostatic Neoplasms 257 Lung Neoplasms 143 Stomach Neoplasms 120 Neoplasms 95 Squamous Cell Carcinoma of Head and Neck 92 Neoplasm Metastasis 80 Head and Neck Neoplasms 76 Esophageal Neoplasms 62 Ovarian Neoplasms 49 Pancreatic Neoplasms 37 Urinary Bladder Neoplasms 35 Nasopharyngeal Carcinoma 35 Sarcoma 34 Triple Negative Breast Neoplasms 28 Carcinoma, Squamous Cell 27 Adenocarcinoma 24 Carcinoma, Ovarian Epithelial 23 Adenocarcinoma of Lung 22 Esophageal Squamous Cell Carcinoma 21 Adenocarcinoma Of Esophagus 21 Recurrence 20 Carcinoma, Transitional Cell 20 Breast Neoplasms, Male 19 Parkinson Disease 4, Autosomal Dominant Lewy Body 18 Melanoma 17 Fallopian Tube Neoplasms 17 Carcinoma 16 Unspecified Adult Solid Tumor, Protocol Specific 15

Interventions

Docetaxel 1 CEF regimen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01110291 2010-04-27

Docetaxel

University of Turku

CYP3A Phenotyping

Data powered by HemOnc (CC BY 4.0) Colophon ⚡